OLDSMAR, Fla.–(BUSINESS WIRE)– Voorafgaand aan de Europese lancering op het veertiende Aesthetic & Anti-Aging Medicine World Congress (AMWC) deze maand, onthult UVLrx Therapeutics™ met blijdschap zijn systeem voor intraveneuze lichttherapie, het model UVL1500. Dit middel biedt hulp bij het herstel van patiënten na een al dan niet operationele cosmetische behandeling. De UVL1500 vermindert ontstekingen en pijn en versnelt wondgenezing. Het bedrijf is begonnen met het verzamelen van patiëntgegevens die aantonen dat de door UVLrx gebruikte golflengtes in licht voordelen bieden bij het terugdringen van ontstekingen, een belangrijk punt bij niet-invasieve cosmetische procedures.
Intravenous Light Therapy Demonstrates Huge Potential for Aesthetic Medicine
OLDSMAR, Fla.–(BUSINESS WIRE)– In anticipation of its official European launch at the 14 th Aesthetic & Anti-Aging Medicine World Congress (AMWC) this month, UVLrx Therapeutics™is pleased to share its intravenous light therapy treatment system, the model UVL1500, to assist in aesthetic post-surgical and non-surgical patient recovery by reducing inflammation, pain, and accelerating wound repair. The company has started to collect patient data that showcases the benefits of light wavelengths utilized by its UVLrx™ Treatment System* for reducing inflammation, a key issue following invasive and non-invasive aesthetic procedures today.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160330006331/en/
The UVLrx Station™ Model UVL1500 offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths for treating a variety of medical indications. Using the company’s patent-pending Dry Light Adapter™ and a standard IV catheter, the device treats blood intravenously, thus eliminating the need for removal of blood from the body. (Photo: Business Wire)
“According to the International Society of Aesthetic Plastic Surgery, more than 20 million cosmetic surgical and non-surgical procedures were performed in 2014,” said Michael Harter, CEO and president of UVLrx. “The success of those procedures depends heavily on quality of recovery and patient response, which is why inflammation abatement is so important for the industry. By immediately reducing inflammation caused by an aesthetic procedure, our technology may minimize pain and accelerate healing, which in turn may lead to better results and a more satisfied post-op patient.”
Dr. Daniel Knight, MD, and Denise Moss, RN, in conjunction with White Clover Wellness & Research Center in Shreveport, Louisiana, have clinical trial results that demonstrate recovery improvement using an investigational device version of the UVLrx technology (Model UVL1000) by reducing pain, edema and erythema in several of their post-surgical/non-surgical aesthetics patients. In fact, all fifteen patients they treated recently in the clinical trial reported improvement in overall quality of life and confidence in their recovery progression. The patients’ positive perception of their improved recovery even appeared to translate into the patients’ perception of how successful the results of their aesthetic procedures were overall, in some cases even accelerating results.
In this clinical trial, patients were treated and subsequently monitored across four evaluation points: baseline and days 3, 7 and 14 post-procedure. Subjects reported improvement by day 3 evaluation, and no adverse effects have been observed. UVLrx patients reported a significant reduction in pain and presented with impressive clinical results days after undergoing non-surgical procedures such as transdermal ultrasound skin tightening, which has often been described as painful and requiring several months to observe clinical results. The level of post-procedural progress observed in this study by day 7 resembled results typically observed in months 2 and 3 post procedure.
“Aesthetic physicians’ work is judged not only by procedural results but also by their patients’ recovery experiences,” commented Rowland Hanson, chairman of UVLrx. “Given the recent Centers for Disease Control and Prevention (CDC) guidelines regarding opiates in the U.S., we expect physicians to seek alternative pain management therapies such as the UVLrx™ Treatment System in order to avoid prescribing addictive and potentially fatal painkillers. Because many aggressive aesthetic procedures have required powerful opiates in the past, intravenous light therapy has the potential to mitigate this crisis and help aesthetics patients who suffer from post-procedural pain.”
Ultraviolet Blood Irradiation (UBI) has been used for over a century to treat bacterial and viral infections and was awarded a Nobel Prize for treating lupus in 1903. Routinely used in hospitals around the world, this form of light therapy fell out of prominence in the U.S. with the advent of antibiotics in the 1950s. With the recent expansion of drug-resistant infections, blood irradiation offers significant advantages to pharmaceutical therapies. Furthermore, UVLrx’s intravenous system is superior to existing ultraviolet blood irradiation (UBI) in that it does not require removal of blood from the body.
To learn more, visit UVLrx.com and stop by the UVLrx Therapeutics booth (F18) at the 14 th Aesthetic & Anti-Aging Medicine World Congress from March 31 st to April 2 nd. To watch a webinar about UVLrx’s technology, please visit https://youtu.be/_WxFjQIekzM.
The UVLrx Station™ Model UVL1500 is not available for sale in the U.S.
* References to published specific wavelength studies available upon request.
About UVLrx Therapeutics
Based in Oldsmar, Florida, UVLrx Therapeutics is dedicated to evidence-based medicine in the field of light therapy and offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths for treating a variety of medical indications. In addition to two Nobel Prizes and NASA-backed research, hundreds of international clinical trials have verified the health benefits of UV and other wavelengths of light utilized in the UVLrx™ Treatment System. For more information, please visit http://uvlrx.com.